Although discussion is ongoing regarding the appropriate cut off for cTnT, 1 the use of cTnT in the diagnosis of acute myocardial infarction (AMI) has greatly enhanced diagnostic sensitivity and further improved risk stratification. Cardiac troponin determinations are not required for diagnosis or treatment of classic ST segment elevation myocardial infarction, as thrombolysis is administered solely on the basis of ECG criteria. It is noteworthy, however, that within a clinical population any rise in cTnT above the detection limit of the assay is related to an increased risk of death. 2 Recent studies of highly trained endurance athletes completing ultraendurance exercise have reported isolated increases of cardiac troponins in the absence of acute coronary symptoms. 3 To date, only limited investigation has examined cTnT after more readily accessible and increasingly popular events such as the London Marathon in less well trained people. Accordingly, we investigated the impact of running the London Marathon on circulating cTnT in a heterogeneous cohort of non-elite runners.
METHODS

Data were collected at the 2002 and 2003 London Marathons.
Following local ethics approval, we obtained written informed consent from 72 runners (mean (SD) age 35 (9) years) to participate in the study. On the basis of a self reported history all participants were apparently healthy, free from cardiovascular disease, and non-medicated. Whole blood samples were drawn, a standard 12 lead ECG was recorded, and standard echocardiography was performed 24 hours before the race and within 30 minutes of race completion. Indices of left ventricular diastolic (ratio of early to late ventricular filling (E:A)) and systolic (end systolic volume-pressure relation) function were calculated. Serum samples were analysed for cTnT with the third generation immunoassay (Roche Diagnostics, Lewes, UK). The assay imprecision was 5.5% at 0.32 mg/l and 5.4% at 6 mg/l, and had a detection limit of 0.01 mg/l and an upper limit of 25 mg/l. Data were analysed for normality by the KolmogorovSmirnov test. Age, completion time, and functional indices were all normally distributed (p . 0.05). The cTnT data were, however, skewed (p , 0.05), probably because of the large number of samples below the assay detection limit. Owing to the abnormal distribution of the cTnT data, analyses was completed by determining the percentage of subjects with a rise in cTnT above the current suggested AMI cut off (0.05 mg/l) 1 and a number of previously suggested AMI cut offs (0.01, 0.03, and 0.1 mg/l).
1 Pearson correlation coefficients were calculated between increases in cTnT and age, completion time, and indices of left ventricular function.
RESULTS
Mean (SD) completion time of the marathon was 253 (48) minutes. Before the marathon all cTnT samples were below the 0.01 mg/l detection limit of the assay. After race completion 56 subjects (78%) had cTnT concentrations above 0.01 mg/l (range 0.012-0.733 mg/l). Of these, 42 (58%) had concentrations above 0.03 mg/l, 26 (36%) above the current AMI cut off (0.05 mg/l), and eight (11%) above 0.1 mg/l. 
DISCUSSION
Within the present study minimally increased serum concentrations above 0.01 mg/l of cTnT were widely observed after marathon running in non-elite runners in the absence of any ECG abnormalities. In addition cTnT concentrations exceeded all or some of the previously examined cTnT cut off criteria.
1 Left ventricular filling was significantly different after race completion; however, no relation was observed between cTnT rise and altered diastolic filling. The significance of an increased cTnT after prolonged exercise may be confused by clinical findings, such as dyspnoea, chest tightness, and possible ECG abnormalities 4 occasionally observed in athletes after prolonged exercise. Accordingly, caution is advised on the use of cTnT cut off criteria in the diagnosis of AMI in patients who have recently completed a bout of prolonged exercise. Although not assessed within the present study, previous studies of highly trained athletes suggest that, 24 hours after completion of a prolonged bout of exercise, cardiac troponin concentrations return below the lower limit of detection. 3 Further, previous research indicates that changes in cardiac function following prolonged exercise are also transient. 5 The aetiology of exercise induced cTnT release and alterations in cardiac function is unclear. However, the widespread increases in cTnT within the present study suggest that the phenomenon is probably physiological. Increased coronary artery shear stress, oxidative stress, and ischaemia have been suggested as potential mechanisms, all of which are mediated by prolonged exercise. 5 The relatively low concentrations of cTnT observed in the present study may result from leakage from the cytosol as opposed to the breakdown of the contractile apparatus. Cytosolic release of cTnT might result from membrane damage propagated by any of the conditions outlined previously. Work is warranted to elucidate further the mechanisms responsible for both exercise induced cTnT release and exercise induced changes in diastolic function. Moreover, the possible long term consequences of exercise induced cTnT release need to be examined. In a clinical setting, elevations in cTnT should be assessed with reference to prolonged exercise as well as typical symptoms of AMI. Context: The benefit of weight reduction for cardiovascular disease (CVD) outcomes remains uncertain. Objective: To examine the effects of baseline body mass index on major CVD outcomes and diabetes over a 20 year follow up, and of weight change in the first five years over the subsequent 15 years. Design and setting: A prospective study of British men followed up for 20 years. Participants: Men aged 40-59 years with no diagnosis of CVD or diabetes (n = 7176) of whom 6798 provided full information on weight change five years later. Outcome measures: Major CVD events (fatal and non-fatal myocardial infarction and stroke, angina, ''other'' CVD deaths) and diabetes. Results: During the 20 year follow up there were 1989 major CVD events and 449 incident cases of diabetes in the 7176 men. Risk of major CVD and diabetes increased significantly with increasing overweight and obesity. During the 15 year follow up, weight gain was associated with increased risk of CVD and diabetes. Weight loss was associated with lower risk of diabetes than the stable group irrespective of initial weight. No significant cardiovascular benefit was seen for weight loss in any men, except possibly in considerably overweight (BMI 27.5-29.9 kg/m 2 ) younger middle aged men (RR = 0.42; 95% CI 0.22 to 0.81). Conclusion: Long term risk of CVD and diabetes increased significantly with increasing overweight and obesity. Weight loss was associated with significant reduction in risk of diabetes but not CVD, except possibly in considerably overweight younger men. Duration and severity of obesity seem to limit the cardiovascular benefits of weight reduction in older men.
